Contineum Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.39.

EBIT: As of FY2026 Q1, the actual value is USD -19.41 M.

Contineum Therapeutics, Inc. reported its first-quarter 2026 financial results, highlighting key financial and operational metrics .

Cash and Liquidity

As of March 31, 2026, cash, cash equivalents, and marketable securities totaled $246.3 million . Cash and cash equivalents were $20.158 million, a decrease from $75.603 million as of December 31, 2025 . Marketable securities increased to $226.170 million as of March 31, 2026, from $187.293 million as of December 31, 2025 .

Operating Expenses

Research and development expenses for the first quarter of 2026 were $11.6 million, representing a 15 percent decrease from $13.712 million in the first quarter of 2025 . This decrease was primarily due to the completion of the PIPE-307 VISTA trial and lower costs for the PIPE-791 PET trial, partially offset by increased expenses for the PIPE-791 IPF program and higher employee-related costs . General and administrative expenses rose by 20 percent to $5.3 million in the first quarter of 2026, compared to $4.398 million in the first quarter of 2025, mainly driven by higher stock-based compensation and employee-related costs . Total operating expenses for the quarter were $16.904 million, down from $18.110 million in the prior year’s first quarter .

Net Loss and Comprehensive Loss

Net loss for the three months ended March 31, 2026, was -$14.5 million, an improvement from a net loss of -$16.0 million for the first quarter of 2025 . Interest income increased to $2.505 million in Q1 2026 from $2.250 million in Q1 2025 . Other expense, net, was -$0.057 million compared to -$0.130 million in the same periods, respectively . Total other income, net, was $2.448 million in Q1 2026, up from $2.120 million in Q1 2025 . Comprehensive loss for the quarter was -$14.969 million, compared to -$15.891 million in the first quarter of 2025 . Net loss per share, basic and diluted, was -$0.39 for Q1 2026, compared to -$0.62 for Q1 2025 .

Balance Sheet Highlights

Total current assets were $252.964 million as of March 31, 2026, decreasing from $267.917 million as of December 31, 2025 . Total assets were $261.349 million as of March 31, 2026, down from $276.642 million as of December 31, 2025 . Total current liabilities decreased to $6.657 million from $9.744 million, and total liabilities decreased to $11.308 million from $15.653 million over the same period . Total stockholders’ equity was $250.041 million as of March 31, 2026, compared to $260.989 million as of December 31, 2025 .

Operational Milestones

Contineum Therapeutics, Inc. reported positive topline data on April 30, 2026, from its exploratory Phase 1b trial of PIPE-791 for chronic osteoarthritis pain or chronic low back pain, meeting its primary safety and tolerability objective . Patients treated with PIPE-791 showed numerically greater pain improvements from baseline compared to the placebo arm . The company initiated patient dosing in PROPEL-IPF, a global Phase 2 clinical trial for PIPE-791 in idiopathic pulmonary fibrosis (IPF), in the first quarter of 2026 . Additionally, Johnson & Johnson began recruiting for a Phase 2 Moonlight-1 trial of PIPE-307/JNJ-89495120 in December 2024, with an estimated completion in June 2026 .

Outlook

Contineum Therapeutics, Inc. believes its cash resources are sufficient to fund planned operations through mid-2029 . This projected cash runway extends approximately one year past the estimated completion of its IPF trial . The company maintains a disciplined approach to capital allocation, prioritizing its lead clinical indication while considering other programs .